GO:1990231 STING complex: Assembly and Research

The STING complex (GO:1990231) is a cellular_component defined as a protein dimer containing two STING monomers that binds cyclic purine di-nucleotides. This complex is a central hub of cytosolic innate immune sensing, converting detection of microbial or self-DNA into transcriptional programs that defend the host. The official GO definition states that activation of the STING complex by 2',5'-3'-5'-cyclic GMP-AMP activates nuclear transcription factor kB (NF-kB) and interferon regulatory factor 3 (IRF3), which then induce transcription of the genes encoding type I IFN and cytokines active in the innate immune response. Because the STING complex sits at the intersection of infection, autoimmunity, and cancer immunosurveillance, it is a high-value target for mechanistic and translational research [1,3,4]. Understanding its composition, assembly, and regulation enables researchers to design precise CRISPR models that dissect its role in disease [1,3,4].

In our own words, GO:1990231 describes the STING complex as a dimeric assembly of two STING monomers that functions as a cyclic dinucleotide receptor. Upon binding 2',5'-3'-5'-cyclic GMP-AMP, the complex initiates signalling that activates NF-kB and IRF3, leading to transcription of type I interferon and innate immune cytokine genes. This definition places the STING complex as a membrane-associated adaptor platform in the endoplasmic reticulum that translates cytosolic nucleic acid detection into immune gene expression.

The STING complex is important because it is a primary signalling platform for cytosolic DNA sensing and innate immune activation. Its dimeric architecture and ligand-binding capacity allow it to convert a small cyclic dinucleotide signal into broad transcriptional reprogramming through NF-kB and IRF3. Because these pathways control type I interferon and cytokine production, the STING complex influences host defense, autoinflammation, and antitumor immunity [1,3,4]. Recent work shows that cysteine allostery and autoinhibition govern human STING oligomer functionality, indicating that the complex is not a simple on/off switch but a finely tuned machine. Additionally, COPA silences STING, revealing that intracellular trafficking pathways actively restrain STING complex activity. These features make GO:1990231 a critical term for immunology, cell biology, and therapeutic discovery [1,3,4].

The following genes and proteins are central to the composition, regulation, and downstream signalling of the STING complex (GO:1990231).

The STING complex is regulated at multiple levels. Cysteine allostery and autoinhibition govern human STING oligomer functionality, meaning that redox-sensitive cysteines and autoinhibitory conformations control whether the complex can signal. COPA silences STING, providing a trafficking-dependent negative regulatory mechanism. In addition, the complex is activated by 2',5'-3'-5'-cyclic GMP-AMP, which triggers NF-kB and IRF3 and subsequent type I IFN and cytokine transcription. These layers of regulation ensure that STING complex activity is tightly controlled to avoid excessive inflammation [1,3,4].

Because the STING complex drives type I interferon and cytokine transcription through NF-kB and IRF3, inappropriate activation can contribute to autoinflammatory and autoimmune pathology. Defects in upstream DNA clearance, such as loss of TREX1, can lead to cytosolic DNA accumulation and STING complex activation. Understanding these mechanisms is essential for developing targeted therapies that modulate STING complex activity [1,3].

The STING complex is central to innate immune sensing that supports antitumor immunity. Activation of the complex by cyclic dinucleotides induces type I IFN, which is critical for immune cell recruitment and tumor control. Conversely, dysregulated STING complex signalling can promote inflammation that supports tumor progression, making context-dependent regulation important [1,3].

The STING complex is a key host defense pathway against pathogens, and many microbes have evolved strategies to evade or suppress it. COPA-mediated silencing of STING illustrates how host trafficking pathways can restrain the complex, and pathogens may exploit similar mechanisms. Studying STING complex regulation in infection models can reveal new therapeutic targets [1,4].

Chronic activation of innate immune signalling, including the STING complex, has been linked to neuroinflammatory processes. While direct evidence for STING complex in specific neurological diseases continues to emerge, its role in type I IFN and cytokine production provides a mechanistic link to inflammation-driven pathology [1,3].

Because STING complex activation induces type I IFN and cytokine genes through NF-kB and IRF3, RNA-seq and targeted qPCR of IFNB1, CXCL10, IL6, and TNF are standard methods to measure activity. These readouts can be used in knockout and point-mutation models to determine which components are required for gene induction [1,3].

The STING complex is a dimer of two STING monomers, so co-immunoprecipitation, native PAGE, and crosslinking can assess dimer formation. Tagged knock-in models enable pull-down and mass spectrometry to identify interacting partners and post-translational modifications [1,3].

STING is an endoplasmic reticulum adaptor, and fluorescence microscopy of tagged STING can track its localization and trafficking. This is particularly useful for studying how COPA and other trafficking proteins influence STING complex distribution.

CRISPR knockout screens can identify genes that regulate STING complex activity, including negative regulators like COPA. Library screening combined with IFN reporter assays enables unbiased discovery of STING complex modulators [1,4].

Researchers studying STING complex-related genes often need to determine whether a candidate gene is causally involved in complex assembly, ligand sensing, or downstream NF-kB and IRF3 activation [1,3,4]. Precise genetic models are essential to separate correlation from causation in innate immune signalling.

The STING complex (GO:1990231) is a dimeric innate immune signalling platform that binds cyclic purine di-nucleotides and activates NF-kB and IRF3 to induce type I IFN and cytokines. Its regulation by cysteine allostery, autoinhibition, and COPA-mediated silencing highlights the sophistication of its control [3,4]. Researchers can leverage CRISPR knockout, point-mutation, knock-in, and overexpression models to dissect its roles in infection, autoimmunity, and cancer [1,3,4]. EDITGENE provides end-to-end services to accelerate this research with publication-ready models and bioinformatics support [1,3,4].